Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 5 Fast-growings companies in Ribociclib
by Most Patent Filing In 5 Years in the United States in 2022

The Ribociclib top 5 is Discovery PatSnap’ annual ranking of the top 5 Most Patent Filing In 5 Years Ribociclib Fast-growings in the United States. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2022, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Ribociclib (trade name Kisqali) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.
#
Company Name
Region
Tech Topics
Total
1
University of Tennessee Research Foundation
Patent: 4
2
Olema Pharmaceuticals, Inc.
Biopharmaceutical,Health care,Estrogen receptor,
...[+2]
Patent: 4
3
Teva Pharmaceuticals USA, Inc.
Trade partner,Corporate social responsibility,Medicine,
...[+2]
Patent: 2
4
Board of Regents of The University of Oklahoma
Radio broadcasting station,Radio broadcasting,Broadcasting
Patent: 2
5
Olaris, Inc.
Substance abuse,Health care,Biotechnology,
...[+2]
Patent: 1
Page generation time: Jul 07 2025